KURA ONCOLOGY, INC. Pre-Tax Income
KURA ONCOLOGY, INC. (KURA) reported Pre-Tax Income of -$68.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-12
- KURA ONCOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$68.32M.
- KURA ONCOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$73.33M.
- KURA ONCOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$80.93M.
- KURA ONCOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$74.12M.
- KURA ONCOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$278.37M.
- KURA ONCOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$171.97M.
- KURA ONCOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$152.63M.
- KURA ONCOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$135.84M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$68.32M 10-Q · filed 2026-08-12 | -$141.65M 10-Q · filed 2026-08-12 | -$222.57M derived: sum of 3 quarters · filed 2026-08-12 | -$296.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$73.33M 10-Q · filed 2026-05-12 | -$154.25M derived: sum of 2 quarters · filed 2026-05-12 | -$228.37M derived: sum of 3 quarters · filed 2026-05-12 | -$294.49M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$80.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$155.04M derived: sum of 2 quarters · filed 2026-03-05 | -$221.17M derived: sum of 3 quarters · filed 2026-08-12 | -$278.37M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$74.12M 10-Q · filed 2025-11-04 | -$140.24M derived: sum of 2 quarters · filed 2026-08-12 | -$197.44M 10-Q · filed 2025-11-04 | -$214.64M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$66.12M 10-Q · filed 2026-08-12 | -$123.33M 10-Q · filed 2026-08-12 | -$140.52M derived: sum of 3 quarters · filed 2026-08-12 | -$194.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$57.20M 10-Q · filed 2026-05-12 | -$74.40M derived: sum of 2 quarters · filed 2026-05-12 | -$128.81M derived: sum of 3 quarters · filed 2026-05-12 | -$179.64M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$17.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$71.60M derived: sum of 2 quarters · filed 2026-03-05 | -$122.44M derived: sum of 3 quarters · filed 2026-03-05 | -$171.97M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$54.40M 10-Q · filed 2025-11-04 | -$105.24M derived: sum of 2 quarters · filed 2025-11-04 | -$154.77M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$50.84M 10-Q · filed 2025-08-07 | -$100.36M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$49.52M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | -$152.63M 10-K · filed 2026-03-05 | |||
| 2022-12-31 | -$135.84M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |